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Abstract 
Background. Animal data and postmortem studies suggest a role of oxidative stress in the 
Huntington’s disease (HD), but in vivo human studies have been scarce. Aim. To assess the 
presence of oxidative stress in HD patients and its occurrence relative to the clinical 
symptoms. Methods. Oxidative stress markers were determined in plasma of HD patients 
(n=19), asymptomatic HD gene carriers (with >38 CAG repeats) (n=11) and their respective 
sex and age-matched healthy controls (n=47 and n=22) in a cross-sectional study. Results. 
With adjustment for age and sex, HD patients had higher plasma lipid peroxidation (LP) 
levels (ratio 1.20, 95% CI 1.09 to 1.32, p<0.001) and lower reduced glutathione (GSH) levels 
(ratio 0.72, CI 0.55 to 0.94, p=0.011) than their age and sex-matched controls. Although 
considerably younger, HD gene carriers did not differ from HD patients regarding LP and 
GSH levels, and had higher plasma LP (ratio 1.16, CI 1.02 to 1.32, p=0.016) and lower GSH 
than their matched controls (ratio 0.73, CI 0.5 to 1.05). They had higher LP (ratio 1.18, CI 
1.02 to 1.34, p=0.019) and lower GSH (ratio 0.75, CI 0.51 to 1.11) than the healthy subjects 
matched to HD patients. Conclusions. Oxidative stress is more pronounced in HD patients and 
asymptomatic HD gene carriers than in healthy subjects. Differences in plasma LP and GSH 
are in line with the brain findings in animal models of HD and might be indicative of the brain 
processes. Data suggest that oxidative stress occurs before the onset of the HD symptoms. 
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Introduction 
Huntington’s disease (HD) is a fatal neurodegenerative disorder with autosomal dominant 
inheritance. It leads to progressive dementia, psychiatric disturbances and incapacitating 
choreiform symptoms culminating in premature death [11]. HD is caused by expansion of a 
CAG trinucleotide repeat on chromosome 4 in exon 1 of the gene coding for a protein of 
unknown function named huntingtin [13]. The CAG expansion results in a series of 
uninterrupted glutamine residues and when it exceeds 38 repeats the pathological variant of 
huntingtin is produced, which causes the disease [22, 29]. The neurological symptoms are due 
to selective neurodegeneration that predominantly affects the basal ganglia [3]. The exact 
cause of neuronal death in HD is unknown; however oxidative stress may play an important 
role [20]. Excessively increased levels of a number of markers of oxidative stress have been 
reported in the areas of degeneration in the brain affected by HD. These include oxidative 
damage products such as malondialdehide, 8-hydroxydeoxyguanosine, 3-nitrotyrosine and 
heme oxygenase [4]. Whether oxidative stress is a primary event or merely a secondary 
constituent of the cell death remains to be established. 
The occurrence of oxidative stress in HD is supported by postmortem studies, while studies 
monitoring in vivo parameters of oxidative stress in HD patients have been scarce. We aimed 
to assess the presence of oxidative stress in HD patients and its occurrence relative to the 
occurrence of clinical symptoms of the disease. For this purpose, we determined markers of 
oxidative stress in the blood of healthy subjects, asymptomatic HD gene carriers and 
symptomatic HD patients. We also assessed the relationship between the oxidative stress 
markers and symptom severity in HD patients. 
 
Patients and methods 
This was a monocentric cross-sectional study approved by the local Ethics Committee at the 
Zagreb University School of Medicine Clinical Hospital Center. 
Patients 
Eligible for inclusion were symptomatic HD patients, asymptomatic HD gene carriers and 
healthy volunteers (HV). Two groups of HVs were planned: one matched by sex and age (±5 
years) to HD patients, and the other one matched to HD gene carriers. A common inclusion 
criterion was a written informed consent, while subjects suffering from any kind of a chronic 
inflammatory disease, diabetes mellitus, chronic heart failure, anemia or a malignant disease 
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were not to be included in the study. HD was diagnosed by a senior neurologist (M.R. or 
T.B.) based on specific clinical features in persons with a positive family history. 
Asymptomatic HD gene carriers were defined as subjects with a proven increased number of 
CAG repeats (≥ 38) in the huntingtin gene with positively excluded presence of clinical 
symptoms of HD, and were recruited among the HD patients’ family members. Healthy 
volunteers were defined as subjects not related to HD patients or HD gene carriers, and were 
enrolled based on personal and family medical history and neurological and psychiatric 
assessment proving a lack of neurological/psychiatric disorders. 
A total of 19 symptomatic HD patients and 11 asymptomatic HD gene carriers were enrolled. 
Their respective age and sex-matched control groups comprised 47 (10 patients had 2 matches 
and 9 had 3 matches) and 22 healthy volunteers (each HD carrier had 2 matches). 
Assessment of the symptom severity and functional testing in HD patients 
HD symptoms were evaluated using the Unified Huntington’s Disease Rating Scale (UHDRS) 
[14]. The scale assesses primary features of HD yielding several scores: motor, cognitive, 
behavioral and a score of functional abilities. The motor subscale rates clinical features of the 
disease: chorea, dystonia, gait, speech, oculomotor movements, rigor, bradykinesia and 
postural stability. It allows for assessment of a total motor score and a total chorea score. The 
behavioral subscale monitors severity and frequency of behavioral problems. The functional 
part is based on three scales: independence scale, total functional capacity scale and a 
functional checklist. The cognitive part consists of three tests: digit symbol modality test, 
verbal fluency and Stroop interference test. All tests were scored using the raw scores. The 
scales were administered during a.m., always by the same investigator (N.K.). 
Blood sampling and sample handling 
For a period of at least 10 days before the blood sampling, the subjects were to be free of any 
acute disease and were not to take any medication apart from that prescribed for treatment of 
HD. Blood samples (5 ml) were taken between 7:00 and 8:00 a.m., after a nights rest. EDTA 
was used as an anticoagulant. Plasma was separated by centrifugation (1000xg, 10 minutes at 
+4°C). Both plasma and the cellular pellet were immediately frozen at -50°C until the 
analysis. 
DNA analysis 
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Amplification of the CAG triplet repeat region in the HD gene was performed by Expand 
Long PCR system (Roche Diagnostics, Mannheim Germany) as previously reported [12]. To 
determine the precise number of the CAG triplets primers HD1 and HD3 were used that 
exclude adjacent CCG repeat region in the HD gene [28]. PCR products containing CAG 
repeats were resolved through 10% polyacrylamide gels and the precise CAG triplet number 
was determined by comparison to the products of the known CAG size.  
Determination of the plasma markers of oxidative stress 
All chemicals used for determination of the oxidative stress markers were purchased from 
Sigma (Taufkirchen, Germany), if not specified otherwise. Superoxide dismutase (SOD), 
superoxide anion (O2*), thiobarbituric acid reactive substances as indicators of lipid 
peroxidation (LP), carbonyl proteins (CarbP), catalase activity (CAT) and the reduced 
glutathione (GSH) were determined spectrophotometrically (Ultraspec 1000 E Pharmacy 
Biotech spectrophotometer). Plasma proteins were determined by the Lowry method [19]. 
Plasma SOD was determined as described by Marklund [21]. The method is based on 
inhibition of the O2*-mediated autooxidation of 0.2 mmol/L pyrogallol by SOD at pH 8.2 and 
20% O2. Pyrogallol autooxidation results in increased absorbance at 420 nm (A420) over 
several minutes, at a rate of 0.02 min-1. Inhibition of autooxidation results in inhibition of A420 
increase. One unit of SOD is defined as an amount required to inhibit the reaction by 50%. 
Briefly, the assay mixture to which 100 µL of plasma sample was added (total volume 1.0 
mL, pH 8.2, aerated 20% O2) contained 50 mmol/L Tris-HCl buffer, 0.2 mmol/L pyrogallol 
and 1 mmol/L diethylenetriaminopentaacetic acid (Fe2+ chelator). All samples were processed 
in the same run. Intra-assay variability assessed as relative standard deviation for 10 samples 
of 100 ng/mL of bovine (Zn-Cu) SOD (Merck, Darmstadt, Germany) was 8%. SOD in the 
samples (U/mL) was determined against a standard curve and is expressed as U/mg plasma 
protein. 
Plasma level of O2* was determined based on reduction of ferricytochrome c [15]. Briefly, 
100 µL of 20 µmol/L ferricytochrome c solution was added to 50 µL of the plasma sample 
and absorbance at 550 nm was measured immediately and after 3 minutes. Absorbance was 
corrected for absorbance determined in the presence or 50 U/mL SOD, and superoxide-
specific reduction of cytochrome c was quantified based on the absorbance difference 
between the first and the second measurement using an extinction coefficient of 2.1 x 104 
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(mol/L)-1 • cm-1. The O2* level is expressed as µmol/L • mL-1 • min-1. All samples were 
assayed in the same run. 
Plasma LP was determined by measuring thiobarbituric acid reactive substances [23]. The 
method is based on the fact that malondialdehyde, a specific secondary product of lipid 
peroxidation, reacts with thiobarbituric acid at pH 3.5 to form a colored complex with a 
maximum absorbance at 532 nm. Briefly, 500 µL of 0.8% thiobarbituric acid in water (w/v) 
and 1.25 mL of 20% trichloracetic acid (w/v) were added to 200 µL of the plasma sample, 
and the mixture was incubated in a water bath at 100°C for 1 hour. After cooling, samples 
were washed once with 4.0 mL of n-butanol/pyridine (1:1, v/v). The n-butanol layer was 
separated by centrifugation (3000xg, 20 minutes), and used for spectrophotometric 
measurements. The amount of pigment reflecting the amount of thiobarbituric acid reactive 
substance was determined using an extinction coefficient of 1.56 × 105 (mol/L)−1 • cm−1. The 
level of LP is expressed as µmol/mL plasma. All samples were assayed in the same run. 
Plasma CarbP were estimated as described by Levine [18]. Briefly, 500 µL of 10 mmol/L 2,4-
dinitrophenylhydrazine (DNPH) in 2 N HCl (w/v), or 500 µL of 2 N HCl as a blank control, 
was added to 50 µL of a plasma sample. The mixture was incubated for 1 hour at room 
temperature. Proteins were precipitated with an equal volume of 20% trichloroacetic acid and 
were washed three times with ethanol/ethyl acetate (1:1, v/v). The final precipitate was 
redissolved in 1 mL of 6 mol/L guanidine hydrochloride and 20 mmol/L potassium phosphate 
buffer (pH 2.3). The absorbance of the DNPH derivatives was measured at 360 nm. The 
carbonyl concentration was determined using an extinction coefficient of 21.5 (nmol/L)-1 • 
cm-1, and is expressed as nmol/mg plasma proteins. All samples were assayed in the same run. 
Plasma CAT (E.C.1.11.1.6.) was determined as described by Johansson and Borg [16]. The 
method is based on reaction of the enzyme with methanol in the presence of an optimal 
concentration of hydrogen peroxide, which results in formation of formaldehyde. In reaction 
with Purpald, formaldehyde forms a chromophore, which is quantified spectrophotometrically 
at 540 nm. Briefly, 100 µL of phosphate buffer (pH 7.0), 40 µL of methanol and 20 µL of 
hydrogen peroxide were added to 50 µL of the plasma sample. The mixture was incubated at 
room temperature for 20 minutes. Reaction was stopped by addition of 50 µL of phosphate 
buffer and 100 µL of 34.2 mmol/L Purpald. Quantification of the chromophore was carried 
out by comparing the sample absorbance with those obtained with formaldehyde calibrators. 
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CAT is expressed as µmol/mg plasma protein. All samples were assayed in the same run. 
Intra-assay variability (as relative standard deviation for 10 determinations of 0.1 nmol/L of 
formaldehyde) was 11%.  
Plasma GSH was assessed as described by Lang [17]. In brief, proteins in 100 µL of a plasma 
sample were precipitated with 50 µL of 20% trichloracetic acid and removed by 
centrifugation (4000xg, 10 minutes), while 100 µL of 0.5 mmol/L 5,5’-dithiobis-2-nitro 
benzoic acid (color reagent) was added to the resulting supernatant. Absorbance at 412 nm 
was determined, GSH was quantified through a comparison with GSH standards and 
expressed as µmol/mL plasma. All samples were assayed in the same run. Intra-assay 
variability (as relative standard deviation for 10 samples of a 0.1 µmol/mL GSH standard) 
was 10%. 
Statistics 
Summary statistics is reported for the measured variables. In the preliminary analysis, HD 
patients and asymptomatic HD gene carriers were compared to their respective matched 
healthy controls. Mann-Whitney test or Chi2 test were used as appropriate. Differences are 
reported with 95% confidence intervals (CIs), which in the case of median differences were 
exact 95.2% CIs. Oxidative stress parameters found significantly different for both HD 
patients and asymptomatic HD gene carriers as compared to their respective controls in the 
preliminary analysis were analyzed further taking into consideration all four groups of 
subjects simultaneously. A non-parametric one-way analysis of variance followed by Kruskal-
Wallis z-test with Bonferroni adjustment for multiple comparisons was implemented. To 
adjust for the effects of sex and age, the analysis was repeated on logarithmically transformed 
(base e) data by applying analysis of variance (group, sex, age). Least square means were 
used to determine differences between the groups expressed as geometric means ratios with 
Tukey-Kramer simultaneous 95% CI. Spearman rank correlation coefficients were determined 
between each of the oxidative stress parameters and each of the motor, cognitive, functional 
and behavioral tests results in the group of symptomatic patients. We used SAS for Windows 
System release 9.1 (SAS Inc., Cary, NC, USA). 
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Results 
HD patients were slightly older (median difference 4 years) and asymptomatic HD gene 
carriers were slightly younger (median difference -4 years) than their respective matched 
healthy volunteer controls (see Table 1, Table 2). As compared to their respective controls, 
both HD patients and HD gene carriers had higher plasma lipid peroxidation (p<0.001 and 
p=0.009, respectively) and lower plasma GSH levels (p=0.006 and p=0.012, respectively). 
Other oxidative stress parameters did not significantly differ between HD patients or HD gene 
carriers and their respective controls (see Table 1, Table 2). 
---insert Table 1--- ---insert Table 2--- 
To further evaluate lipid peroxidation and GSH levels the four groups of subjects were 
considered simultaneously, in an unadjusted (non-parametric analysis of variance) and 
adjusted analysis (analysis of variance on ln-transformed data with adjustment for age and 
sex). The two analyses yielded similar results for either of the two parameters, with 
significant “group” effects (see Fig. 1, Table 3).   ---insert Table 3--- 
Lipid peroxidation was higher in HD patients than in their matched controls (p<0.001 in both 
analyses), and the adjusted analysis indicated a difference of around 20% (see Fig. 1, Fig. 2). 
Although younger, HD carriers were comparable to HD patients regarding lipid peroxidation. 
HD carriers had higher lipid peroxidation than their matched controls (p=0.012 and p=0.016 
in the unadjusted and adjusted analysis, respectively), and the adjusted analysis indicated a 
difference of around 16% (see Fig. 1, Fig. 2). Although younger, HD carriers had higher lipid 
peroxidation than healthy volunteers matched to HD patients, as well. The difference did not 
attain statistical significance in the unadjusted analysis (p=0.016 vs. the statistical 
significance limit 0.0125) (see Fig. 1), but was significant in the adjusted analysis (p=0.019) 
and was estimated at around 18% (see Fig. 2). 
---insert Fig. 1--- ---insert Fig. 2--- 
Plasma GSH level was lower in HD patients than in their matched controls (p=0.005 and 
p=0.011 in the unadjusted and adjusted analysis, respectively). The difference was estimated 
at around -28% (see Fig. 1, Fig. 2). HD gene carriers were comparable to HD patients 
regarding GSH. They had lower GSH levels than either of the two control groups, but the 
differences failed (by small amounts) to attain statistical significance. In the adjusted analysis, 
the difference between HD carriers and their matched controls was estimated at around -27%, 
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and the difference between HD carriers and controls matched to HD patients was estimated at 
around -25% (see Fig. 1, Fig. 2). 
Correlation analysis of oxidative stress parameters and clinical features in HD patients (n=19) 
indicated the following associations: higher plasma lipid peroxidation and worse outcomes in 
the verbal fluency test (Spearman rho -0.620, p=0.012), Stroop word test (Spearman rho -
0.496, p=0.05) and a worse total chorea score (Spearman rho 0.497, p=0.036). 
 
Discussion 
Oxidative stress, defined as an imbalance between oxidant production and antioxidant 
protection, has been linked to many neurological disorders [2]. High lipid concentration and 
high energy requirements make the brain particularly susceptible to free radical and oxidant-
mediated insults. A growing body of evidence suggests that HD may have components of the 
free radical and oxidative stress-induced injury [10]. The most compelling evidence comes 
from animal studies. For example, systemic administration of 3-nitropropionic acid produces 
lesions that closely resemble the neuropathological features of HD. The lesions are associated 
with increased markers of free-radical damage and are significantly attenuated in mice 
overexpressing superoxide dismutase, an enzyme that protects against the free radicals [6]. 
Due to a high content of polyunsaturated fatty acids and transition metals like iron and 
copper, the brain is particularly vulnerable to lipid peroxidation and accumulating evidence 
substantiates extensive interactions between the reactive oxygen species and neuronal lipids in 
the brain areas directly involved in the HD process [1, 5]. Recently, higher levels of lipid 
peroxidation products in plasma were reported in a sample of patients with advanced HD as 
compared to healthy subjects [7, 26]. This finding was associated with alterations of 
tryptophan metabolism in the kynurenin pathway in HD patients, and tryptophan metabolits 
(kynurenines) are assumed to modulate reactive oxygene species generation (and oxidative 
stress) either directly, or through interactions with the NMDA glutamate receptor [26]. It was 
concluded that the changes detected in the peripheral blood did, although likely to a limited 
extent, reflect the processes going on in the brain [26]. In line with those observations, in the 
present study we found significantly higher plasma levels of lipid peroxidation in HD patients 
than in the age and sex-matched healthy controls. The observed difference of around 20% is 
lower than the one reported by others [7, 26]. This could be due to two facts: first, our HD 
patients were mostly outpatients with a moderately advanced disease, while those considered 
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by others (n=11) suffered from a very advanced disease and were permanently disabled [7, 
26]; second, in the present study HD patients were only slightly older than the control subjects 
(median difference 4 years), while the mean difference in age between HD patients and 
healthy controls in the previous reports was 17 years [7, 26]. Furthermore, we found 
significantly higher (by around 16%) levels of plasma lipid peroxidation in asymptomatic HD 
gene carriers (>38 CAG repeats in the huntingtin gene) than in their age and sex-matched 
healthy controls. Although HD gene carriers were considerably younger than HD patients, 
their lipid peroxidation levels were comparable to those found in HD patients and were 
significantly higher (by around 18%) than the levels in healthy subjects matched by age to HD 
patients. Despite the limitation of a cross-sectional design (as opposed to a prospective 
longitudinal follow-up), the results suggest that an increase in lipid peroxidation precedes the 
occurrence of the clinical symptoms of HD. To the extent to which plasma levels of lipid 
peroxides may be considered illustrative of the processes going on in the brain, the current 
observations appear to be in line with data directly relating progression of lipid peroxidation 
in the brain and progression of the neurological phenotype in mice transgenic for the HD 
mutation [24]. Associations between higher lipid peroxidation levels and worse total chorea 
score, worse verbal fluency score and worse results in the Stroop word test in HD patients 
observed in the present study may be viewed as circumstantial evidence to support a role of 
lipid peroxidation in the onset/progression of the clinical symptoms of HD. 
Reduced gluthation is an important defense mechanism that protects cellular constituents from 
the damaging effects of peroxides. Decreased GSH levels are indicative of oxidative stress 
and are associated with cell damage, progression of aging and certain neurodegenerative 
disorders [8, 9]. A single post-mortem study found no difference in basal ganglia GSH levels 
between HD patients and subjects without neurodegenerative disorders, while the level of 
oxidized glutathione was reduced in the HD patients’ caudate nucleus [25]. On the other hand, 
the rat model of HD with lesions induced by 3-nitropropionic acid is characterized by a 
marked depletion of the striatal GSH [27]. In parallel with higher plasma lipid peroxidation 
levels, HD patients in the present study had significantly lower (by around 28%) plasma GSH 
levels than their age and sex-matched controls. Similarly, HD gene carriers were comparable 
to HD patients regarding GSH, and had lower GSH levels than their age and sex-matched 
controls (by around 27%) or healthy subjects matched by age to HD patients (by around 
25%). Although these differences failed to attain statistical significance (by small amounts), 
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the patterns of differences in plasma GSH levels among the four groups paralleled the pattern 
of differences in lipid peroxidation levels as a “mirror image”, and appeared to be in line with 
the animal data on reduced basal ganglia GSH in experimental HD [27].  
Taken together, the current results demonstrate the presence of oxidative stress in HD patients 
illustrated by a higher plasma level of lipid peroxidation products and a lower level of 
oxidant-protective GSH as compared to healthy controls. The observed differences may be 
reasonably viewed as indicative of the processes going on in the brain [7, 26] and are in line 
with the brain findings in animal models of HD. The same pattern of differences found in 
asymptomatic HD gene carriers (with > 38 CAG repeats) as compared to age and sex-
matched controls and the lack of differences between HD gene carriers and HD patients 
suggest that oxidative stress occurs before the onset of HD symptoms and support a role of 
oxidative stress in pathophysiology of HD. 
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Table 1. Demographics and oxidative stress parameters in plasma: Huntington’s disease patients (HD patients) and age and sex-matched healthy 
volunteers (matched HV). Data are counts (percentages) or medians (ranges). Differences between groups are given with 95% confidence 
interval (CI).  
  HD patients Matched HV  HD – HV (95% CI) P-value* 
N  19 47  --- --- 
Males  14 (74) 31 (66)  8 (-18.1 to 29.0) 0.578 
Age (years)  46 (18-58) 41 (21-58)  4 (-2 to 10) 0.195 
HD duration (years)  5 (0.5–14) NA  --- --- 
CAG repeats (number)  45 (40-66) NA  --- --- 
O2* (µmol/L •mL-1 • min-1)   0.71 (0.10-3.79) 0.58 (0.08-2.36)  0.16 (-0.21 to 0.47) 0.430 
SOD (U/mg plasma protein)  0.96 (0.09-2.68) 0.96 (0.02-3.95)  0.04 (-0.34 to 0.72) 0.392 
CAT (µmol/mg plasma protein)   35.3 (19.4-56.3) 29.9 (19.2-68.1)  2.51 (-1.67 to 9.52) 0.326 
LP (µmol/mL plasma)  13.3 (8.95-15.9) 10.2 (7.30-13.7)  2.77 (1.7 to 3.43) <0.001 
GSH (µmol/mL plasma)  8.21 (3.54-13.6) 11.4 (6.1-19.2)  -2.92 (-5.56 to -1.13) 0.006 
CarbP (nmol/mg plasma protein)  2.30 (0.90-3.92) 1.98 (0.04-5.34)  0.27 (-0.25 to 0.99) 0.266 
* From Chi2 test for proportions or Mann-Whitney test for medians 
NA not applicable, HD Huntington disease, O2* superoxide anion, SOD superoxide dismutase, CAT catalase, LP lipid peroxidation, GSH reduced 
gluthatione, CarbP protein carbonyls 
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Table 2. Demographics and oxidative stress parameters in plasma: asymptomatic Huntington’s disease gene carriers (HD carriers) and age and 
sex-matched healthy volunteers (matched HV). Data are counts (percentages) or medians (ranges). Differences between groups are given with 
95% confidence interval (CI).  
  HD carriers Matched HV  HD-HV (95%CI) P-value* 
N  11  22  --- --- 
Males  6 (55) 12 (55)  0 1.000 
Age (years)  23 (17-30) 25.5 (17-31)  -4 (-8 to 0) 0.083 
CAG repeats (number)  46 (42-65) NA  --- --- 
O2* (µmol/L •mL-1 • min-1)   0.47 (0.12-4.73) 0.49 (0.10-2.32)  -0.017 (-0.55 to 0.47) 0.858 
SOD (U/mg plasma protein)  0.89 (0.24-2.89) 1.29 (0.02-4.91)  -0.32 (-0.88 to 0.66) 0.553 
CAT (µmol/mg plasma protein)   40.4 (19.2-54.8) 27.0 (22.0-55.0)  6.32 (-1.94 to 15.5) 0.105 
LP (µmol/mL plasma)  13.0 (9.20-14.2) 10.3 (8.41-12.1)  1.80 (0.60 to 2.97) 0.009 
GSH (µmol/mL plasma)  8.48 (7.01-14.1) 13.8 (6.1-18.5)  -4.20 (-6.59 to -0.66) 0.012 
CarbP (nmol/mg plasma protein)  2.88 (0.40-4.80) 1.72 (0.88-4.83)  0.76 (0 to 1.44) 0.050 
* From Fischer exact test for proportions or Mann-Whitney test for medians. 
NA not applicable, HD Huntington disease, O2* superoxide anion, SOD superoxide dismutase, CAT catalase, LP lipid peroxidation, GSH reduced 
glutathione, CarbP protein carbonyls 
Table 3. Summary of analysis of variance on logarithmically transformed values of plasma 
lipid peroxidation (Ln LP) and reduced glutathione (Ln GSH) in Huntington’s disease patients 
(n=19), asymptomatic Huntington’s disease gene carriers (n=11) and their respective matched 
healthy controls (n=47 and n=22). 
   Ln LP  Ln GSH 
 Df  F ratio P-value  F ratio P-value 
Model 4  7.82 <0.001  4.18 0.002 
Age 1  0.83 0.365  2.53 0.115 
Sex 1  0.30 0.585  0.12 0.727 
Group 2  12.02 <0.001  5.14 0.003 
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Fig. 1 Plasma lipid peroxidation and reduced glutathione levels in HD patients (n=19), 
asymptomatic HD gene carriers (n=11) and their respective sex and age-matched healthy 
controls (HV) (n=47 and n=22). Box plots display medians (diamonds), quartiles (boxes), 
inner fences (bars) and outliers (circles). P-values are from one-way non-parametric analysis 
of variance (“all groups”), followed by Kruskal-Wallis z-test for multiple pairwise 
comparisons. Four comparisons of interest were carried out with Bonferroni adjustment, so 
that p-values <0.0125 were considered statistically significant. 
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Fig. 2 Adjusted pairwise differences in plasma lipid peroxidation and reduced glutathione 
levels for HD patients (n=19), HD gene carriers (n=11) and their respective age and sex-
matched healthy volunteer controls (HV) (n=47 and n=22). Least-square mean differences 
from analysis of variance on ln-tranformed parameters with factors age, sex and group (main 
effects given in Table 3) are shown as geometric means ratios (exponents) with 95% 
simultaneous Tukey-Kramer confidence intervals.  
 
 
Fig. 3 Correlation between plasma lipid peroxidation and verbal fluency score, Stroop word 
test score and total chorea score in HD patients (n = 19) 
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